On Friday, Amylyx Pharmaceuticals stock hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 98, up from 83 the day before.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength. This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners tend to have an 80 or better RS Rating in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Amylyx Pharmaceuticals Stock A Buy?
Amylyx Pharmaceuticals stock has climbed more than 5% past a 23.26 entry in a first-stage ipo base, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
In terms of top and bottom line numbers, Amylyx Pharmaceuticals has posted rising EPS growth over the last two quarters. Sales gains have been less impressive, coming in at -100% in the latest report.
Amylyx Pharmaceuticals stock earns the No. 198 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharma, Genmab and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
